🔴 enGene Holdings is trading 7% down in pre-market with no clear catalyst identified

enGene Holdings is trading at $1.60 (-7.01%) in pre-market, with no specific catalyst identified.

• The company’s press-release page shows no recent release for November 5.
• Biotech strength offered a contrasting backdrop: Amgen reported better-than-expected third-quarter earnings and raised its full-year outlook, but this does not explain enGene Holdings’ decline.
• Available evidence does not establish a clear connection to broader market conditions.